Sign In

Malcolm McColl

CEO and Co-Founder ImmVirX Pty Ltd

Malcolm McColl is a seasoned professional with over 25 years of global management experience in the pharmaceutical and biotechnology industries. He has held various senior executive roles, with a strong focus on oncology. One of his significant achievements includes leading Viralytics as CEO, culminating in its acquisition by Merck and Co for $A502m. Prior to this, he was Vice President Business Development at Starpharma, overseeing partnering activities and programs.

Highlights

Mar 25 · linkedin

Delighted to provide an update on progress @ImmVirX with some early promising signals in the phase 1a study in #ColorectalCancer patients. Lots of milestones ahead including commencement  of the phase 1b combo with an immune checkpoint in mid year

Feb 21 · linkedin

Delighted to announce our collaboration with leading Chinese biopharma company Innovent Biologics.  We will assess our IVX037 with Innovent’s Chinese market leading anti-PD1 TYVYT®. Excited to explore the powerful potential of the combination in colorectal, gastric and ovarian cancer patients.

https://lnkd.in/gNfmXVxp

Malcolm McColl
Add to my network

Location

Greater Melbourne Area